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Abstract	In	recent	years,	undifferentiated	small	round	cell	sarcomas	(USRCSs)	have	been	divided	 into	 a	 variety	 of	 new,	 rare,	 sarcoma	 subtypes,	 including	 the	 group	 of	Ewing-like	 sarcomas,	 which	 have	 the	 morphological	 appearance	 of	 Ewing	
sarcomas,	but	carry	CIC	–DUX4,	BCOR	–CCNB3	and	other	gene	fusions	different	from	 the	 classic	 EWSR1–ETS	 gene	 fusion.	 Using	 high-throughput	 RNA-sequencing	 (RNA-seq)	 analyses,	 we	 identified	 a	 novel	 recurrent	 gene	 fusion,	CRTC1–SS18,	in	two	cases	of	USRCS	that	lacked	any	known	translocation.	RNA-seq	results	were	confirmed	by	reverse	transcription	polymerase	chain	reaction,	long-range	polymerase	chain	reaction,	and	fluorescence	in	situ	hybridization.	In	vitro,	we	showed	that	the	cells	expressing	the	gene	fusion	were	morphologically	distinct	 and	had	 enhanced	oncogenic	 potential	 as	 compared	with	 control	 cells.	Expression	 profile	 comparisons	 with	 tumours	 of	 other	 sarcoma	 subtypes	demonstrated	 that	 both	 cases	 clustered	 close	 to	 EWSR1–CREB1-positive	tumours.	 Moreover,	 these	 analyses	 indicated	 enhanced	 NTRK1	 expression	 in	CRTC1	 –SS18-positive	 tumours.	 We	 conclude	 that	 the	 novel	 gene	 fusion	identified	 in	 this	 study	 adds	 a	 new	 subtype	 to	 the	 USRCSs	 with	 unique	 gene	signatures,	and	may	be	of	therapeutic	relevance.		Diagnosing	 small	 round	 blue	 cell	 tumours	 on	 biopsy	 has	 been	 challenging	because	 of	 their	 lack	 of	 specific	 features	 in	 small	 specimens.	 Among	undifferentiated	small	round	cell	sarcomas	(USRCSs),	Ewing-like	sarcoma	(ELS)	shares	some	of	the	morphological	features	of	Ewing	sarcoma	(ES),	but	lacks	the	classic	 EWSR1–ETS	 gene	 fusion	 [1,2].	 ESs	 are	 mainly	 characterized	 by	chromosomal	translocations	at	chromosome	22q12	that	fuse	EWSR1	with	one	of	the	ETS	gene	family	of	transcription	factors,	such	as	FLI1	or	ERG,	in	90–95%	of	ES	cases.	The	classic	ES	gene	fusion	protein	acts	as	an	oncoprotein,	and	plays	an	essential	role	in	tumourigenesis	and	proliferation	of	ES	cells	[2].	Recent	studies	have	 identified	 recurrent	 gene	 fusions	 in	 ELS,	 namely	 CIC–DUX4	 and	 BCOR–CCNB3	[3–6].	The	identification	of	these	gene	fusions	suggests	that	other,	as	yet	to	 be	 identified,	 gene	 fusions	 could	 be	 associated	 with	 this	 type	 of	 tumour.	Furthermore,	 novel	 gene	 fusions	 in	 ELS	 have	 been	 reported	 recently	 in	 case	reports,	 including	 CIC–FOXO4,	 BCOR–MAML3,andZC3H7B–BCOR	 [7–9].	Identifying	 these	 genetically	 defined	 entities	 may	 contribute	 towards	understanding	the	pathogenesis	and	the	behaviour	of	these	tumours.	By	 applying	 RNA	 sequencing	 (RNA-seq)	 technology	 to	 investigate	 USRCS,	 we	discovered	a	novel	CRTC1–SS18	gene	fusion	in	two	samples	 from	two	different	cancer	centres.	Combining	both	samples,	we	were	able	to	find	similarities	at	the	clinical,	patholog-ical,	and	molecular	levels.	Moreover,	by	cloning	the	fusion	gene	we	were	able	to	demonstrate	 its	oncogenic	properties,	adding	the	CRTC1–SS18	fusion	gene	to	the	increasing	number	of	described	oncogenes.			
Materials	and	methods	One	patient	sample	(case	1)	was	obtained	from	the	Royal	Orthopaedic	Hospital	NHS	Foundation	Trust	Tumour	Bank	(with	permission;	REC	12/EM/0048).	The	other	patient	sample	(case	2)	was	obtained	from	resection	material	sent	to	the	Centre	Léon	Bérard	 for	molecular	diagnosis.	Both	 samples	were	 acquired	with	informed	consent	from	the	patient	and	or/next	of	kin,	and	ethical	approval	from	institutional	 and	 local	 research	 commit-tee	 boards.	 Patient	 samples	 were	anonymized	 and	 used	 in	 accordance	 with	 the	 principles	 expressed	 in	 the	Declaration	of	Helsinki.		
	
Immunohistochemistry	
Case	1	For	 immunohistochemistry,	 2-μm-thick	 sections	 were	 cut,	 and	 antigens	 were	retrieved	 in	 an	 epitope	 retrieval	 solution	 of	 pH	 8	 (RE7116;	 Novocastra,	Newcastle	upon	Tyne,	UK)	at	68	∘C	for	17	h	in	a	stirred	water	bath.	The	antibody	clones,	dilutions	and	sources	were	as	follows:	anti-CD99	(12E7,	1:25;	Dako,	Ely,	UK),	anti-vimentin	(V9,	1:100;	Novocastra),	anti-CD31	(JC70,	1:100;	Dako),	anti-CD34	(QBend10,	1:50;	Dako),	anti-cytokeratin	AE1/AE3	(1:100;	Dako),	 anti-CD45	 (2B11	 +	 PD7/26,	 1:200;	 Dako),	 anti-cytokeratin	 MNF116	(1:50;	Dako),	anti-desmin	(D33,	1:100;	Dako),	anti-α-smooth	muscle	actin	(SMA)(1A4,	1:200;	Dako),	anti-epithelial	 membrane	 anti-gen	 (EMA)	 (E29,	 1:100;	 Dako),	 anti-HMB45	 (1:200;	Dako),	 anti-S100	 (NCL-L-S100p,	 1:1000;	 Novo-castra),	 anti-Wilms	 tumour	 1	(WT1)	 (C-19,	 1:500;	 Santa	Cruz,	 Insight	Biotechnology	Limited,	Wembley,	UK),	anti-TLE1	(M-101,	1:50;	Santa	Cruz),	anti-ERG	(Erg-1/2/3	C-1,	1:50;	Santa	Cruz),	anti-INI1	 [1:25;	 BD	 Transduction	 Laboratories	 (BD	 Biosciences),	 Becton	Dickinson	UK,	 Oxford,	 UK],	 anti-BCOR	 (C-10,	 1:50;	 Santa	 Cruz),	 anti-ETV4	 (16,	1:50;	Santa	Cruz),	and	anti-Ki67	(MIB1,	1:200;	Dako).		
Case	2	Sections	were	cut	at	a	thickness	of	4	μm	from	formalin-fixed	paraffin-embedded	(FFPE)	 tissue,	 and	 immunostained	 with	 a	 VentanaBenchmark	 XT	 automatic	stainer	 (Ventana,	 Tuscon,	 AZ,	 USA).	 Sig-nals	were	 revealed	with	 the	 ultraView	Universal	Dab	Detection	kit	(Ventana).	The	following	antibodies	were	used:	anti-CD99	(12E7;	Dako),	anti-EMA	(E29,	1:50;	Dako),	anti-desmin	(D33,	1:80;	Dako),	anti-cytokeratin	AE1/AE3	(AE1/AE3,	1:50;	Dako),	anti-caldesmon	(h-CD,	1:100;	Dako),	anti-myogenin	(F5D,	1:100;	Dako),	anti-S100	(Z0311,	1:800;	Dako),	anti-CD34	 (QBend-10,	 1:25;	 Dako),	 anti-INI1	 (25,	 1:50;	 BD	 Transduction	Laboratories),	 anti-BCOR	 (C-10,	 1:50;	 Santa	 Cruz),	 and	 anti-ETV4	 (16,	 1:50;	Santa	Cruz).	Immunohistochemistry	for	neurotrophic	receptor	tyro-sine	kinase	1	(NTRK1)	 was	 performed	 with	 a	 32-min	 incubation	 with	 the	 anti-NTRK1	antibody	 (ab76291,	 clot	EP1058Y,	dilution	1:200;	Abcam,	Cambridge,	UK)	on	a	Ventana	ULTRA	machine	with	Cell	Conditioning	Solution	1	pretreatment	for	64	min.	
Fluorescence	in	situ	hybridization	(FISH)	analyses	FISH	analyses	were	performed	on	FFPE	tissue	sections	with	the	ZytoLight	SS18	Dual	 Color	 Break	 Apart	 Probe	 (#Z-2097-200;	 Zytovision,	 Bremerhaven,	Germany)	 by	 assessment	 of	 at	 least	 100	 non-overlapping	 intact	 nuclei	 by	 two	independent	operators.	The	positive	threshold	for	calling	the	FISH	assay	positive	was	15%.	Array-comparative	genomic	hybridization	(aCGH)	analyses	Genomic	 DNA	 was	 extracted	 from	 FFPE	 tissue	 with	 a	 QIAamp	 DNA	micro	 kit	(Qiagen,	Hilden,	Germany).	Genomic	DNA	and	human	reference	DNA	(Promega,	Madison,	WI,	USA)	were	labelled	with	cyanine	5	and	cyanine	3,	respectively,	by	use	of	 the	Genomic	DNA	High-Throughput	ULS	Labeling	Kit	 (Agilent	Technolo-gies,	 Santa	 Clara,	 CA,	 USA),	 and	 co-hybridized	 onto	 a	 4x180K	 Sureprint	 G3	Human	CGH	microarray	(Agilent	Technologies),	according	to	the	manufacturer’s	recommendations.	 Data	 were	 analysed	 with	 Agilent	 Genomic	 Workbench	
software	v7.0	or	with	Cytogenomics	software	(v2.9.2.4;	Agilent),	and	expressed	according	 to	 the	 human	 reference	 genome	 hg19	 (GRCh37;	 Genome	 Reference	Consortium	Human	Reference	37).	The	 identification	of	 aberrant	 copy	number	segments	was	based	on	the	ADM-2	segmentation	algorithm	with	a	threshold	of	6.0.	Fresh	frozen	tissue	RNA-seq	Total	RNA	was	extracted	from	fresh	frozen	tissue	(case	1)	with	a	Qiagen	RNeasy	Mini	 kit	 (Qiagen,	 Hilden,	 Germany)	 according	 to	 the	 manufacturer’s	 protocol.	RNA	 quality	 and	 quantity	 were	 measured	 with	 an	 Agilent	 2100	 bioanalyzer	(Agilent	 Technologies).	 An	 RNA	 sample	 was	 sent	 to	 Oxford	 Gene	 Technology	(Begbroke,	 UK)	 for	 performance	 of	 RNA-seq	 with	 the	 Illumina	 HiSeq	 2000	platform	(Illumina,	San	Diego,	CA,	USA).	 In	brief,	cDNA	libraries	were	prepared	from	1	 μg	 of	 total	 RNA	 with	 the	 Illumina	 TruSeq	 RNA	 Sam-ple	 Prep	 Kit	 v2.	 All	sequencing	 was	 paired-end	 (100	 bp)	 and	 performed	 over	 100	 cycles,	 and	 the	read	 files	 (Fastq)	 were	 generated	 from	 the	 sequencing	 platform	 via	 the	manufacturer’s	 software.	 Mapping	 and	 alignment	 were	 processed	 with	 the	Tuxedo	suit.	The	human	sequence	genome	(hg19)	was	used	as	a	reference	and	aligned	to	the	sequence	reads.	Fusion	Catcher	software	was	used	to	identify	gene	fusions	 from	 RNA-seq	 data	 [10].	 RNA-seq	 data	 have	 been	 deposited	 (SRA	accession:	SRP131744).		
FFPE	RNA	sequencing	RNA	was	 extracted	 from	 FFPE	 tissue	 sections	 (case	 1	 and	 case	 2)	with	 Trizol	reagent	 (Thermo	 Fisher	 Scien-tific,	 Courtaboeuf,	 France),	 and	 subsequently	extracted	 with	 phenol/chloroform.	 The	 RNase-free	 DNase	 Set	 (Qiagen,	Courtabouef,	France)	was	used	to	remove	DNA.	The	DNase	was	eliminated	by	a	further	 Trizol	 extraction.	 All	 RNAs	 were	 quantified	 by	 spectrophotom-etry	(NanoDrop;	Thermo	Fisher	Scientific),	and	qual-	ity	was	controlled	(DV200	value	cutoff	of	>13%)	by	use	of	a	TapeStation	with	Hs	RNA	ScreenTape	(Agi-lent	Technologies).	One	hundred	nanograms	of	total	RNA	was	 used	 to	 prepare	 a	 library	 with	 a	 TruSeq	 RNA	 Access	 Library	 Prep	 Kit	(Illumina).	Fourteen	libraries	were	pooled	at	4	nM	with	1%	PhiX	as	an	internal	control.	 Sequencing	 was	 performed	 (75	 cycles,	 paired	 end)	 with	 a	 NextSeq	500/550	 High	 Output	 V2	 kit	 and	 an	 Illumina	 NextSeq	 500	 (Illumina).	 Align-ments	 were	 performed	 with	 the	 STAR	 algorithm	 [11]	 against	 the	 GRCh38	reference	 genome,	 and	 fusion	 gene	 assessments	were	made	with	 STAR-Fusion	[12],	 Fusion-Catcher	 [10]	 and	 FusionMap	 [13]	 tools.	 Expression	 pro-files	were	extracted	from	fastq	files	with	Kallisto	[14],	and	 transformed	 as	 log2(TPM	 +	 2)	 prior	 to	 quantile	 normalization	 with	 the	Limma	package	v	3.32.2	per-formed	in	the	R	environment	v3.4.1	[15].	Only	genes	with	 a	 coding	 sequence	 annotation	 (based	 on	 Ensembl	 GRCh38p5	 annotation)	and	with	a	maximum	expression	value	 across	 all	 samples	 of	 >2wereconsideredforthe	 clustering	 analysis,	 which	was	 performed	 by	 the	 use	 of	Ward’s	 distance	 on	 the	 10%	most	 variant	 genes	based	 on	 their	 interquartile	 range.	 RNA-seq	 data	 have	 been	 deposited	 (SRA	accession:	SRP131744).	Reverse	 transcription	 polymerase	 chain	 reaction	 (RT-PCR)	 and	 Sanger	sequencing	
cDNA	 was	 generated	 from	 total	 RNA	 with	 Super-Script	 III	 (Invitrogen)	 and	random	primers	(Promega).	The	RT-PCR	reactions	were	performed	withy	2.5	μl	of	10X	buffer,	2.5	μl	of	dNTPs	(2.5	mM),	5	μlof5X	GC-rich	solution,	1	μl	of	forward	primer	(20	pmol),	1	μl	of	 reverse	primer	(20	pmol),	and	0.1	μlofFastStart	DNA	polymerase	 (Roche,	 Burgess	 Hill,	 UK).	 Primer	 sets	 used	 for	 polymerase	 chain	reaction	 (PCR)	 amplification	 were	 CRTC1-F	 (TCGAACAATCCGCGGAAATT)	 and	SS18-R	(GTGCTGGTAAAAGAGACTGCA),	and	PCR	products	were	visualized	with	2%	(w/v)	agarose	gel	 (Bioline,	London,	UK).	The	PCR	products	were	extracted	from	 the	 gel	 and	 purified	 with	 a	 QIAquick	 Gel	 Extraction	 Kit	 (Qiagen,	 Hilden,	Germany).	 A	 BigDye	 Terminator	 V3.1	 kit	 (Applied	 Biosystems,	 Foster	 city,	 CA,	USA)	was	used	 for	 the	 cycle	 sequencing	 reaction,	 and	PCR	products	of	CRTC1-SS18	 gene	 fusions	 were	 directly	 Sanger	 sequenced	 with	 an	 ABI	 3730	 DNA	analyser	(Applied	Biosystems).		Long-range	PCR	(LR-PCR)	LR-PCR	 was	 carried	 out	 with	 PrimeSTAR	 GXL	 DNA	 polymerase	 (Takara	 Bio,	Shiga,	 Japan).	 Each	 LR-PCR	 reaction	 was	 set	 up	 with	 50	 ng	 of	 DNA,	 1	 ×	 5X	PrimeS-TAR	 GXL	 buffer,	 200	 μM	 each	 dNTP,	 0.2	 μM	 forward	 primer,	 0.2	 μM	reverse	primer,	and	1.25	U	of	PrimeS-TAR	GXL	DNA	polymerase	enzyme,	made	up	to	a	final	volume	of	50	μlwithsterilized	distilled	water.	The	PCR	was	carried	out	with	the	following	condi-tions:	30	cycles	of	10	s	at	98	∘Cand10minat60∘C.	 The	 LR-PCR	 primers	 used	 in	 this	 study	 are	 listed	 in	supplementary	material,	 Table	 S1.	 The	 size	 of	 the	 PCR	 product	 from	 the	 gene	fusion	was	unknown;	therefore,	genome	walking	through	both	genes	and	a	rough	esti-mation	of	the	product	size	was	carried	out.	The	genome	walking	covered	the	exonic	 and	 intronic	 regions	 of	 both	 genes	 involved	 in	 the	 fusion.	 LR-PCR	was	performed	on	the	genomic	DNA	of	the	tumour	sample.	One	for-ward	primer	(F3)	was	anchored	on	exon	1	of	CRTC1,and	different	reverse	primers	spanning	∼2.5	kbp	of	intron	1wereused	to	amplify	this	region	 and	 to	 identify	 the	 breakpoint.	 The	 samples	 were	 electrophoresed	 on	0.9%agarose	gels	to	determine	the	size	of	the	PCR	product.	After	confirming	the	breakpoint	 of	 CRTC1–SS18	 gene	 fusion	 at	 the	 genomic	 level,	 LR-PCR	was	 per-formed	 on	 both	 the	 tumour	 sample	 and	 the	 corresponding	 normal	 tissue	 to	confirm	that	this	fusion	was	somatic.	The	PCR	product	was	then	extracted	from	the	gel	and	sequenced.	Plasmid	construction	The	 CRTC1–SS18	 expression	 construct	 was	 made	 by	 PCR	 amplification	 of	 the	entire	fusion	construct	with	the	cDNA	generated	from	case	1	tumour	RNA.	This	amplicon	was	subcloned	into	the	expression	vector	pFlag-CMV-4	(Sigma-Aldrich,	Dorset,	England)	by	the	use	of	EcoRI	and	XbaI	restriction	sites.	The	primers	used	were	 as	 follows:	 forward,	 5′-cg	 g	 aat	 tcg	 aag	 atg	 gcg	 act	 tcg	 aac	 aat	 c-3	 ;and	reverse	 ,5′-cg	 tctaga	 t	 tca	 ctg	 ctg	 gta	 att	 tcc	 ata	 c-3.	 Plasmid	 constructs	were	verified	 by	 sequencing.	 Expression	 of	 this	 plasmid	 generates	 an	 N-terminal	FLAG-tagged	protein.	The	construct	plasmid	and	associated	empty	vector	were	transfected	into	HEK293	cells	(ATCC,	Manassas,	VA,	USA),	clones	were	isolated,	and	 expression	was	 validated	 by	western	 blotting	with	 an	 anti-FLAG	 antibody	(Cat.	 No.	 F1804,	 clone	M2,	 1:1000;	 Sigma-Aldrich).	 Clones	were	maintained	 in	
Dulbecco’s	modified	Eagle’s	medium	(DMEM)	and	10%	fetal	bovine	serum	(FBS)	supplemented	with	1	mg/ml	G418	(Life	Technologies,	Carlsbad,	CA,	USA).	Cell	migration	assays	Suspensions	containing	25	000	cells	of	a	stable	CRTC1–SS18-expressing	HEK293	clone,	 or	 a	 clone	 containing	 the	empty	vector,	 suspended	 in	 serum-free	DMEM	were	seeded	into	a	24-well	format	Boyden	chamber	cell	culture	insert	(8-μmporesize;	PET	membrane)	(BD	Falcon,	Bedford,	MA,	USA).	The	lower	chamber	contained	DMEM,	and	10%	FBS	as	an	attractant.	Chambers	were	 incubated	 for	 16	 h.	 Cells	were	 fixed	 in	methanol;	 cells	 on	 the	upper	side	of	the	chamber	were	removed,	and	those	remaining	on	the	underside	were	 stained	with	 crystal	violet.	Migrated	cells	were	photographed,	 the	 crystal	violet	was	 solubilized	 in	500	μl	 of	 33%acetic	 acid,	 and	 the	optical	 density	was	measured	at	540	nm	(n	=	20).		
Cell	invasion	assays	Amodified	migration	assay	was	 carried	out	 in	which	50	000	 cells	were	 seeded	into	Boyden	chambers	(8-μmpore	size;	PET	membrane)	(BD	Falcon)	pre-coated	with	 100	 μl	 of	 Geltrex	 basement	membrane	matrix	 (Thermo	 Fisher	 Scientific).	Chambers	were	 incubated	 for	16	h.	 Invasive	cells	were	counted	by	microscopy	with	the	observer	unaware	of	the	cell	type	(n	=	22).		
Soft	agar,	anchorage-independent	growth	assay	Anchorage-independent	 growth	 in	 soft	 agar	 was	 assessed	 with	 the	 CytoSelect	96-Well	 Cell	 Transforma-tion	 Assay	 kit	 (Cell	 Biolabs,	 San	 Diego,	 CA,	 USA),	according	 to	 the	manufacturer’s	 instructions.	 In	brief,	2500	cells	per	well	were	seeded	in	agar	supplemented	with	DMEM	and	10%	FBS.	Following	incubation	for	8days,	 the	 agar	 was	 solubilized	 and	 viable	 cells	 were	 lysed,	 stained	 and	quantified	by	fluorometry	(excitation	492	nm,	emission	520	nm;	n	=	8).			
Results	
Clinical	presentation	and	pathological	findings	of	the	index	case,	case	1	
Clinical	presentation	A35-year-old	man	 presented	 to	 the	 Royal	 Orthopaedic	 Hospital	with	 a	 rapidly	growing	lump	on	his	right	thigh.	Magnetic	resonance	imaging	revealed	a	heterogeneous	mass	within	the	sartorius	muscle,	and	the	findings	were	in	keeping	with	a	soft	tissue	sarcoma.	A	diagnosis	of	USRCS	was	made	on	 the	biopsy	material	of	 the	 tumour,	which	did	not	carry	the	 chimeric	 gene	 fusions	 associated	 with	 ES	 (EWSR1–FLI1	 or	 EWSR1–ERG),	mesenchymal	 chondrosarcoma	 (EWS–NR4A3	 and	 TAF2N–NR4A3),	 DSRCT	(EWS–WT1),	 or	 synovial	 sarcoma	 (SS)	 (SS18–SSX).	 The	 tumour	 was	 also	 neg-ative	 for	 CIC–DUX4	 and	 BCOR–CCNB3.	 In	 view	 of	 this	 diagnosis,	 the	 patient	received	 four	 cycles	 of	 vincristine,	 ifosfamide,	 doxorubicin	 and	 etoposide.	Radiologically,	 there	 was	 no	 response	 to	 chemotherapy,	 and	 the	 mass	 was	excised.	 The	 patient	 developed	 bilat-eral	 lung	 metastases	 18	 months	 after	diagnosis,	and	died	of	disease	92	months	later.	
Pathological	findings	Grossly,	an	intramuscular,	well-circumscribed	greyish	white	fleshy	tumour	with	haemorrhagic	and	necrotic	foci	
measuring	7	×	65	×	53	mm	was	observed	(Figure	1A).	Histologically,	the	tumour	consisted	 of	 solid	 sheets	 and	 nests	 of	 small	 round	 cells	 surrounded	 by	desmoplastic	 stroma	 reminiscent	 of	 desmoplastic	 small	 round	 cell	 tumour	(DSRCT).	 The	 tumour	 cells	 had	 scant	 amounts	 of	 eosinophilic	 cytoplasm	 and	small,	 irregularly	 shaped	 round	 nuclei	 with	 stippled	 chromatin.	 Some	 had	prominent	grooves	and	small	nucleoli.	Focal	areas	of	necrosis	and	mitotic	figures	were	 identified	 (seven	 per	 10	 high-power	 fields).	 Rosette	 formation	 and	glandular	 differentiation	 were	 not	 identified	 (Figure	 1B,C).	Immunohistochemically,	 the	 tumour	 cells	 were	 diffusely	 positive	 for	 vimentin	and	CD99	(Figure	1D).	The	tumour	cells	did	not	stain	for	CD31,	CD34,	AE1/AE3,	CD45,	CK(MNF116),	desmin,	EMA,	HMB45,	SMA,	S100,	HMB45,	WT1,	TLE1,	ERG,	ETV4,	BCOR,	or	CCNB3.	 INI1	expression	was	retained.	The	Ki67	 labelling	 index	was	up	to	20%.	
RNA-seq	analysis	and	confirmation	of	gene	fusion	RNA-seq	 analysis	 of	 the	 index	 case	 (case	 1)	 revealed	 anovelgene	fusioninvolvingCRTC1	and	SS18	in	the	tumour	sample.	Two	alternative	splicing	fusion	 tran-scripts	were	 detected	 that	 linked	 exon	 1	 of	 CRTC1	with	 exon	 2	 or	exon	 3	 of	 SS18	 (Figure	 2A,B;	 supplementary	 material,	 Figure	 S1).	 A	 balanced	translocation	resulted	in	SS18	being	fused	with	exon	1	of	CRTC1,	generating	an	in-frame	 fusion	 protein	 (Figures	 2A,B	 and	 4A).	 The	 CRTC1–SS18	 fusion	transcripts	 were	 confirmed	 by	 RT-PCR	 and	 Sanger	 sequencing	 (Figure	 2B;	supple-mentary	material,	Figure	S2A).	In	order	to	map	the	fusion	breakpoints	at	the	 genomic	 level,	 LR-PCR	 was	 carried	 out	 to	 reveal	 the	 genomic	 sequence	around	 the	breakpoints	 (supplementary	material,	 Figure	S2B–D	and	Table	S1).	The	CRTC1	breakpoint	was	found	to	be	8bp	from	the	3′-end	of	exon	1	(cDNA	fusion	point),	and	the	SS18	breakpoint	was	4457	bp	before	the	5′-end	of	exon	1	(Figure	2C).	
	
Clinical	presentation	and	pathological	findings	of	case	2	
Clinical	presentation	RNA	sequencing	revealed	a	second	case	of	an	CRTC1–SS18-positive	USRCS	(case	2):	a	42-year-old	woman	who	presented	to	the	CHU	Gui	de	Chauliac	(Montpellier,	France)	 with	 a	 mass	 from	 the	 popliteal	 fossa,	 later	 diagnosed	 as	 an	undifferentiated	 small	 cell	 sarcoma.	 The	 patient	 underwent	 radiotherapy	 and	chemotherapy	prior	 to	 the	surgical	 removal	of	 the	 tumour.	A	 tumour	 fragment	was	 sent	 to	 the	 Centre	 Léon	 Bérard’s	 department	 of	 pathology	 for	 a	 second	opinion	and	molecular	diagnosis.		
Pathological	findings	An	intramuscular	mass,	well	circumscribed	by	a	diffuse	calcified	 matrix,	 measuring	 110	 ×	 75	 ×	 70	 mm	 was	 observed.	 The	 tumour	consisted	 of	 bundles	 and	 nests	 of	 cells	 embedded	 in	 a	 focally	 myxoid	 fibrous	stroma	(Figure	3A).	There	were	areas	of	necrosis.	Cytologically,	the	tumour	was	composed	of	oval	to	epithelioid	cells	(Figure	3B).	The	cells	were	of	medium	size	with	 abundant	 eosinophilic	 cytoplasm	 and	 ovoid	 and	 vesicular	 nuclei	 with	nucleoli	(Figure	3C).	Immunohistochemically,	the	tumour	cells	were	positive	for	CD99	and	negative	for	keratins,	EMA,	desmin,	caldesmon,	myogenin,	S100,	CD34,	ETV4,	 and	 BCOR.	 INI1	 expression	was	 retained.	 NTRK1	was	 diffusely	 positive.	RNA-seq	 performed	 on	 the	 FFPE	material	 showed	 an	 in-frame	 fusion	 between	
exon	 1	 of	 CRTC1	 and	 exon	 2	 of	 SS18.	 In	 this	 case,	 the	 translocation	 was	unbalanced,	as	demonstrated	by	FISH	(Figures	2A	and	4A).	It	is	of	note	that	the	cell	 morphology	 was	 similar	 in	 the	 tumour	 biopsy	 acquired	 before	 treatment,	which	also	harboured	the	CRTC1–SS18	fusion	gene.	Genomic	and	transcript	profiles	aCGH	analyses	revealed	that	case	1	had	a	diploid	genome	and	a	balanced	CRTC1–SS18	translocation,	whereas	case	2	had	a	tetraploid	genome	with	an	unbalanced	CRTC1–SS18	 translocation	 (see	 Figure	 4B	 for	 specific	 chromosomal	 gains	 and	losses	for	each	case).	To	enable	comparison	of	both	samples,	RNA-seq	of	case	1	was	 also	 performed	 on	 an	 FFPE	 sample,	 in	 the	 same	 pipeline	 as	 case	 2.	Hierarchical	 clustering	 analysis	 (of	 RNA-seq	 data)	 demonstrated	 that	 both	samples	clustered	together	and	close	to	the	EWSR1–CREB1-positive	tumours	but	not	 with	 ESs	 or	 ELSs	 (Figure	 4C).	 Also,	 CRCT1–SS18-positive	 samples	 did	 not	cluster	 with	 the	 recently	 described	 cutaneous	 melanocytomas	 harbouring	 a	CRTC1–TRIM11	fusion	gene	[16].	Furthermore,	RNA-seq	data	revealed	enhanced	NTRK1	 expression	 in	 the	 two	 cases	 with	 the	 CRTC1–SS18	 gene	 fusion	 as	compared	 with	 other	 sarcomas	 with	 known	 translocations	 such	 as	 EWSR1–CREB1,	 BCOR–CCNB3,	 CIC–DUX4,and	 EWSR1–FLI1	 (Figure	 4D),	 and	 this	 was	confirmed	 at	 the	 protein	 level	 by	 immunohistochemistry	 (supplementary	material,	Figure	S3).	Functional	analysis	of	the	CRTC1–SS18	gene	fusion	product	To	determine	whether	the	product	of	the	CRTC1–SS18	gene	fusion	identified	had	any	potential	oncogenic	activity,	 the	 fusion	gene	 from	case	1	was	cloned	 into	a	tagged	mammalian	expression	vector,	and	human	HEK293	clones	expressing	the	construct	were	generated;	a	fusion	protein	of	the	predicted	size	(∼57	kDa)	was	observed	(supplementary	material,	Figure	S4).	The	CRTC1–SS18-positive	 clone	 were	 morphologically	 distinct	 from	 control	 clones,	 showing	extended	 pseudopodia	 and	 pronounced	 intracytoplasmic	 vacuoles	 (Figure	 5A).	We	 proceeded	 to	 assess	 the	 anchorage-independent	 growth	 potential	 of	 these	cells	 (hallmark	 of	 transformation).	 CRTC1–SS18-expressing	HEK293	 cells	were	seeded	into	semisolid	agar,	in	96-well	microtitre	plates,	and	incubated	for	8	days.	The	number	of	viable	cells	was	then	determined	with	a	commercial	fluorescence	assay.	 Following	 this	 relatively	 short	 period	 of	 incubation,	 the	 assay	 indicated	that	there	were	3.7	times	the	number	of	viable	cells	expressing	CRTC1–SS18	as	control	 HEK293	 cells	 transfected	with	 an	 empty	 plasmid.	 This	 increase	 in	 the	number	of	viable	cells	was	statistically	significant	(Figure	5B).	As	expression	of	this	 fusion	 protein	 appeared	 to	 increase	 anchorage-independent	 growth,	 we	continued	to	assess	these	cells	for	other	hallmarks	of	malignancy.	We	carried	out	assays	 to	 determine	 the	migratory	 and	 invasive	 potential	 of	 the	 CRTC1–SS18-expressing	cells.	In	a	Boyden	chamber	assay,	in	which	cells	are	encouraged	 to	 pass	 through	 8-μmpores,	 significantly	 more	 HEK293	 cells	expressing	CRTC1–SS18	migrated	 than	 control	 cells;	 this	was	determined	both	visu-ally	and	with	a	colourimetric	assay	(Figure	5C).	In	a	similar	assay,	in	which	the	membranes	of	the	cham-bers	are	coated	in	a	basement	membrane	matrix	to	model	 the	 invasive	 potential	 of	 these	 cells,	 2.6	 times	 more	 CRTC1–SS18-expressing	 cells	 than	 control	 cells	 invaded	 through	 the	 membrane	 in	 a	 16-h	period	(Figure	5D).			
Discussion	ELS	 or	 USRCS	 is	 a	 subtype	 of	 small	 blue	 round	 cell	 tumour	 that	 has	 a	morphological	 appearance	 close	 to	 that	 of	 ES	 but	 lacks	 the	 characteristic	EWSR1–ETS	 gene	 fusion.	 Recently,	 some	 of	 these	USRCSs	 have	 been	 shown	 to	carry	 gene	 fusions	 involving	 CIC–DUX4,	 CIC–FOXO4,	 BCOR–CCNB3,	 BCOR–MAML3,and	ZC3H7B–BCOR	[3–8].	In	this	study,	we	have	identified,	by	RNA-seq,	a	novel	recurrent	CRTC1–SS18	gene	fusion	in	two	USRCSs	that	were	negative	for	known	 gene	 fusions	 in	 this	 sarcoma	 type.	 The	 CREB-regulated	 transcription	coactivator	 1	 (CRTC1)	 gene	 belongs	 to	 a	 family	 of	 highly	 conserved	 cAMP	response	 element-binding	 protein	 (CREB)	 coactivators	 [17,18].	 CRTC1	 has	already	 been	 implicated	 in	 other	 translocations,	 such	 as	 the	 CRTC1–MAML2	fusion	 in	mucoepidermoid	 carcinoma	of	 salivary,	 bronchial	 and	 thyroid	 glands	[19–22],	 and	 the	 CRTC1–TRIM1	 fusion	 in	 cutaneous	melanocytomas	 [16].	 The	SS18	protein	(NBAF	chromatin	remodelling	complex	sub-unit	SS18)	functions	as	a	 transcriptional	 coactivator,	 and	 interacts	 directly	with	members	 of	 the	 SWI–SNF	chromatin	remodelling	complex	[23].	The	SS18–SSX	fusion	is	a	result	of	the	chromosomal	 translocation	 t(X;18)(p11;q11)	 in	 almost	 all	 cases	 of	 SS,	 which	account	for	approximately	10–20%	of	all	soft	tissue	sarcomas	[24–26].	These	 two	 cases	 of	 CRTC1–SS18-positive	 sarcoma	 are	 regarded	 as	 a	 distinct	entity	from	all	other	ELSs,	DSRCTs	and	poorly	differentiated	SSs	described	in	the	literature.	Poorly	differentiated	SS	is	characterized	by	high	cellularity,	polygonal	to	 small	 round	 cell	 morphology,	 frequent	 mitoses,	 and	 necrosis.	 These	 poorly	differentiated	 SSs	 may	 be	 distinguished	 by	 the	 expression	 of	 high	 molecular	weight	 cytok-eratins	 and	 CD99,	 and	 having	 the	 characteristic	t(X;18)(p11:2;q11:2)	 translocation.	 However,	 these	 two	 cases	 of	 CRTC1–SS18-positive	 sarcoma	 had	 a	 distinct	 morphology	 relative	 to	 that	 seen	 in	 poorly	differentiated	 SS,	 and	 lacked	 the	 characteristic	 t(X;18)(p11:2;q11:2)	translocation.	 Only	 one	 other	 ELS	 tumour	 with	 a	 CIC–FOXO4	 gene	 fusion	 has	been	 described	 with	 desmoplastic	 stroma	 that	 showed	 immunoreactivity	 for	CD99	and	focal	WT1.	This	tumour	occurred	in	the	neck	of	an	elderly	male.	DSRCT	commonly	 arises	 in	 the	 abdominal	 cavity	 in	 children	 and	 young	 adults,	 and	 is	characterized	 histologically	 by	 nests	 of	 small	 round	 cells	 surrounded	 by	desmoplastic	 stroma,	 immunohistochemically	 by	 positive	 staining	 for	 keratins,	desmin,	and	WT1,	and	genetically	by	the	presence	of	a	recur-rent	translocation,	i.e.	t(11;22)(p13;q12).	However,	the	tumours	that	we	describe	here	occurred	in	lower	 limbs	 of	 adult	 patients,	 and	 the	 tumour	 cells	 were	 larger	 than	 cells	 of	DSRCT,	with	more	 cytoplasm,	 and	 showed	 immunoreactivity	 for	 CD99	 but	 did	not	carry	the	EWS–WT1	gene	fusion.	Morphologically,	 the	 two	 tumours	 that	we	 present	 here	 shared	 features:	 large	fibrous	 stroma,	 and	 small	 to	 medium	 cells	 with	 eosinophilic	 cytoplasm	 and	vesicular	 nuclei.	 Expression	 profile	 analyses	 confirmed	 that	 our	 CRTC1–SS18-positive	sarcomas	were	not	related	to	ES	or	ELS,	but	rather	 to	EWSR1–CREB1-positive	 tumours.	 It	 is	 of	 note	 that	 CRTC1–TRIM11-positive	 cutaneous	melanocytomas	were	also	 found	 to	 resemble	EWSR1–CREB1-positive	 clear	 cell	sarcomas	[16],	but	hierarchical	clustering	clearly	separated	both	types	of	CRTC1-fused	tumours.	Finally,	we	also	present	here	evidence,	at	both	the	RNA	level	and	the	 protein	 level,	 that	 NTRK1	 is	 expressed	 at	 higher	 levels	 in	 CRTC1–SS18-positive	 sarcomas	 than	 in	other	 related	 tumours.	We	could	not	 find	any	 fusion	involving	 NTRK1	 in	 these	 tumours,	 explaining	 its	 elevated	 level	 Nevertheless,	
NTRK1	expression	may	be	useful	as	a	marker	for	differential	diagnosis,	but	most	importantly	may	 be	 used	 as	 a	 therapeutic	 target.	 In	 addition,	we	 demonstrate	that	 the	 cells	 expressing	 the	 CRTC1–SS18	 gene	 fusion	 were	 morphologically	distinctive	from	control	cells	and	had	enhanced	oncogenic	potential.	In	summary,	we	have	presented	 two	cases	of	USRCS	with	a	novel	CRTC1–SS18	gene	 fusion.	 It	 would	 be	 beneficial	 to	 screen	 more	 samples	 to	 determine	 the	frequency	 of	 CRTC1–SS18	 gene	 fusion	 in	 other	 USRCSs.	 The	 severe	 clinical	phenotype	 (lung	metastasis	 at	 an	 early	 age)	of	 case	1	 (case	2	has	6	months	of	follow-up),	 the	 novel	 CRTC1–SS18	 gene	 fusion	 and	 the	 expression	 profile	 data	indicate	that	these	tumours	may	be	classified	as	a	new	type	of	USRCS.	Except	for	sporadic	and	unique	cases,	 to	our	knowledge	 the	 two	USRCSs	 in	 this	 study	are	the	only	cases	of	a	sarcoma	type	other	than	SS	involving	SS18	as	a	recurrent	gene	fusion	 partner.	 The	 discovery	 of	 this	 new	 fusion	 should	 enable	 better	classification	 and	 study	 of	 these	 rare	 sarcomas.	 CRTC1–SS18-positive	 sarcoma	should	be	considered	 in	 the	differential	diagnosis	of	USRCS,	DSRCT	and	poorly	differentiated	tumours	that	show	SS18	split	signals	with	FISH.	Elevated	levels	of	NTRK1	 in	 CRTC1–SS18-positive	 sarcomas	 may	 be	 of	 therapeu-tic	 importance	and	amenable	 to	 treatment	with	 tyrosine	kinase	 inhibitors	 [27].	Considered	all	together,	 for	 the	 field	 of	 rare	 to	 ultra-rare	 sarcomas,	 this	 study	 offers	 a	 nice	example	of	the	need	to	assess	samples	from	different	cancer	centres	to	identify	recurrent	fusions	and	to	be	able	to	characterize	new	sarcoma	subtypes.	Further	collaboration	 between	 groups	 is	 therefore	 required	 to	 depict	 the	 whole	landscape	of	small	round	cell	sarcomas.		
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Figure	Legends	
Figure	 1.	 Macroscopy	 and	microscopy	 images	 of	 case	 1.	 (A)	 The	macroscopic	image	shows	a	fairly	well-circumscribed	fleshy	tumour	with	foci	of	necrosis	and	haemorrhage.	 (B)	The	microscopic	 image	(low	power)	shows	the	 tumour	to	be	composed	of	solid	sheets	and	nests	surrounded	by	desmoplastic	stroma.	(C)	The	high-power	 view	 of	 the	 tumour	 shows	 small	 cells	 with	 scant	 cytoplasm.	 (D)	Membranous	staining	with	CD99,	mimicking	ES.		
Figure	 2.	 RNA-seq	 identification	 of	 the	 CRTC1–SS18	 gene	 fusion.	 (A)	 The	genomic	intron–exon	structure	of	CRTC1	(blue)	and	SS18	(red).	CRTC1(exon	1)–
SS18(exon	2)	gene	fusion	was	found	in	case	1	and	case	2,	whereas	CRTC1(exon	1)–SS18(exon	3)	alternative	splicing	gene	fusion	was	found	only	in	case	1.	(B)	A	Sanger	 sequencing	 chromatogram	 of	 the	 RT-PCR	 product	 confirmed	 the	CRTC1(exon	1)–SS18(exon	2)	fusion	junction	and	the	CRTC1(exon	1)–SS18(exon	3)	 fusion	 junction	 in	 case	 1.	 (C)	 Schematic	 of	 the	 exon–intron	 structure	 of	 the	CRTC1–SS18	gene	 fusion	at	 the	DNA	 level.	The	 intergenic	breakpoints	 for	both	genes	 are	 shown,	 and	 were	 confirmed	 by	 Sanger	 sequencing	 of	 the	 LR-PCR	product	in	case	1.		
Figure	3.	Microscopy	 images	of	case	2.	(A)	Haematoxylin	and	eosin	(HE)	(low-power	objective,	×10):	sheets	and	nests	of	cells	 in	desmoplastic	stroma.	(B)	HE	(×20):	nest	of	epithelioid	cells.	(C)	HE	(objective	×40):	cells	were	of	medium	size	with	 abundant	 eosinophilic	 cytoplasm	 and	 ovoid	 and	 vesicular	 nuclei	 with	nucleoli.		
Figure	4.	Genomic	and	transcript	profiles	of	CRTC1–SS18-positive	sarcomas.	(A)	FISH	 analysis	 with	 an	 SS18	 break-apart	 probe,	 showing	 multiple	 copies	 of	chromosome	 18	 carrying	 SS18.	 Most	 cells	 were	 tetrasomic	 or	 greater	 for	 the	SS18	 locus	 on	 chromosome	 19.	 In	 case	 1,	 the	 translocation	 was	 balanced	(presence	of	red	dots),	whereas	in	case	2	the	translocation	was	unbalanced	(the	red	signal	is	lost	while	the	green	signal	remains).	(B)	aCGH	profiles.	Case	1	had	a	diploid	genome	with	the	loss	of	chromosomes	1,	3p,	and	9,	and	parts	of	11q,	17p,	18,	and	22,	together	with	gains	on	chromosomes	3q,	5,	6,	7,	9,	10,	11,	16,	17,	20,	and	21.	The	region	around	SS18	on	chromosome	18	was	focally	gained,	whereas	the	 CRTC1	 locus	 was	 normal,	 which	 is	 in	 accordance	 with	 a	 balanced	translocation.	 Case	 2	 had	 a	 tetraploid	 genome	 with	 the	 loss	 of	 one	 copy	 of	chromosomes	 1,	 3,	 13,	 14,	 17,	 21,	 and	 22,	 and	 with	 homozygous	 deletion	 of	chromosome	 region	 17q22,	 impacting	 on	 MBTD1,	 UTP18,andCA10.The5′	region	of	SS18	(on	the	minus	strand)	and	the	3′	region	of	CRTC1	(on	the	plus	strand)	 were	 lost,	 in	 accordance	 with	 an	 unbalanced	 translocation.	 (C)	Hierarchical	 clustering	 of	 RNA-seq	 data	 placed	 the	 two	 CRTC1–SS18-positive	cases	 close	 to	 EWSR1–CREB1-positive	 tumours.	 (D)	 NTRK1	 expression	 from	RNA-seq	 data.	 AFH/PPMS,	 angiomatoid	 fibrous	 histiocytoma/primary	pulmonary	 myxoid	 sarcoma;	 CCCS,	 cutaneous	 clear	 cell	 sarcoma;	 CM-CT	,cutaneousmelanocytoma	 withCRTC1–TRIM11	 fusion;	 BCR,	 BCOR-rearranged	sarcoma;	CD4,	CIC–DUX4-positive	sarcoma;	EwS,	Ewing	sarcoma.		
Figure	5.	Biological	analysis	of	the	CRTC1–SS18	gene	fusion.	(A)	Morphological	analysis	 of	 CRTC1–SS18-expressing	 cells.	 CRTC1–SS18	 fusion-positive	 clones	were	 morphologically	 distinct	 from	 control	 HEK293	 cells;	 the	 cytoplasmic	component	was	small,	with	pronounced	vacuoles	 and	 extended,	 thin	 pseudopodia	 (both	 images	 taken	 under	 phase	contrast	 at	 ×200	 magnification).	 (B)	 Expression	 of	 the	 CRTC1–SS18	 fusion	protein	 in	HEK293	 cells	 significantly	 increased	 anchorage-independent	 growth	potential.	 The	 number	 of	 viable,	 colony-forming	 cells	 present,	 following	incubation	 in	 soft	 agar,	 was	 increased	 2.1-fold	 in	 HEK293	 cells	 expressing	CRTC1–SS18	as	compared	with	 HEK293	 cells	 transfected	 with	 a	 control	 plasmid.	 Viable	 cells	 were	determined	with	a	 fluorometric	assay.	p	<	0.0001,	 t	=	8.61,	degrees	of	 freedom	
(d.f.)	=	14.	Error	bars	 represent	 standard	error	of	 the	mean	 (SEM)	 (n	=	8).	 (C)	Expression	 of	 the	 CRTC1–SS18	 fusion	 protein	 in	 HEK293	 cells	 significantly	increased	 cell	migration.	The	number	of	HEK293	 cells	 expressing	CRTC1–SS18	that	 migrated	 through	 8-μm	 pores	 in	 a	 Boyden	 chamber	 assay	 in	 16	 h	 was	significantly	increased	as	compared	with	HEK293	cells	transfected	with	a	control	plasmid.	This	was	 apparent	 by	 inspection	by	microscopy	 (at	 ×4objective	magnification)	and	by	a	colourimetric	assay.	p	<	0.0001,	t	=	6.2.2,	d.f.	=	38.	Error	bars	show	SEM	(n	 =	 20).	 (D)	 Expression	 of	 the	 CRTC1–SS18	 fusion	 protein	 in	 HEK293	 cells	significantly	increased	cell	invasive	potential.	 The	 number	 of	 HEK293	 cells	 expressing	 CRTC1–SS18	 that	 invaded	through	 8-μmporescoatedinabasement	 membrane	 matrix	 in	 16	 h	 was	significantly	increased	as	compared	with	HEK293	cells	transfected	with	a	control	plasmid.	 Invasive	 cells	were	 counted	 at	 ×40	 objective	magnification;	 the	mean	number	of	invasive	cells	was	2.6	times	greater	for	CRTC1–SS18-expressing	cells	than	for	control	cells.	p	<	0.0001,	t	=	6.108,	d.f.	=	42.	Error	bars	show	SEM	(n	=	22).	OD,	optical	density.		
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